Spots Global Cancer Trial Database for prolymphocytic leukemia

Every month we try and update this database with for prolymphocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	NCT00098371	B-cell Chronic ... Prolymphocytic ... Refractory Chro...	alvocidib	18 Years -	National Cancer Institute (NCI)
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease	NCT00176475	Leukemia Lymphoma Multiple Myelom...	rituximab therapeutic all...	18 Years -	Rutgers, The State University of New Jersey
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia	NCT02029443	Chronic Lymphoc... Small Lymphocyt... Richter's Syndr... Prolymphocytic ...	Acalabrutinib	18 Years - 130 Years	Acerta Pharma BV
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Treg Cells for AGVHD in Non-myeloablative UCB Transplant	NCT02118311	Hematologic Mal...	T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra...	18 Years - 69 Years	Masonic Cancer Center, University of Minnesota
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	NCT00278213	Prolymphocytic ...	alemtuzumab cyclophosphamid... fludarabine pho... mitoxantrone hy...	18 Years - 70 Years	German CLL Study Group
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma	NCT00278161	Leukemia Lymphoma	Pegfilgrastim Rituximab Cyclophosphamid...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant	NCT02662296	Prolymphocytic ... Recurrent Chron... Recurrent Non-H... Recurrent Small...	Ibrutinib Idelalisib	18 Years -	Fred Hutchinson Cancer Center
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant	NCT01244906	Hematologic Neo...	Allogeneic Hema...	18 Years - 75 Years	Northside Hospital, Inc.
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia	NCT00612612	B-cell Chronic ... Leukemia Prolymphocytic ... Refractory Chro... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni...	obatoclax mesyl... fludarabine pho... rituximab laboratory biom...	18 Years -	National Cancer Institute (NCI)
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)	NCT00364286	Leukemia Lymphoma	Dasatinib (BMS-...	-	M.D. Anderson Cancer Center
Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT00735930	Anemia Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro... Thrombocytopeni...	Alvocidib Hydro... Lenalidomide Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Allogeneic Stem Cell Transplant for CLL	NCT01629511	Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom...	Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus	18 Years - 70 Years	M.D. Anderson Cancer Center
Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11)	NCT00005626	Leukemia Lymphoma	Irinotecan	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT01251575	Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia	NCT00003746	Leukemia	2-chlorodeoxyad... 2-chlorodeoxyad...	18 Years -	Swiss Group for Clinical Cancer Research
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	NCT00005786	Extranodal Marg... Nodal Marginal ... Prolymphocytic ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac...	arsenic trioxid... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	NCT02007044	Prolymphocytic ... Recurrent Chron... Recurrent Small...	Ibrutinib Quality-of-Life... Questionnaire A... Rituximab	18 Years -	M.D. Anderson Cancer Center
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases	NCT02145039	Acute Leukemias Burkitt's Lymph... Chronic Myeloge...	Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ...	- 74 Years	Masonic Cancer Center, University of Minnesota
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer	NCT00602693	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	umbilical cord ... Allopurinol fludarabine pho... Cyclophosphamid... Total body irra... Treg infusion Sirolimus	18 Years - 75 Years	Masonic Cancer Center, University of Minnesota
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT01251575	Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma	NCT00006252	Leukemia Lymphoma	fludarabine pho... Cyclophosphamid... PBSC G-CSF Donor lymphocyt...	- 69 Years	Alliance for Clinical Trials in Oncology
Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia	NCT00021151	Leukemia	alemtuzumab	18 Years -	Case Comprehensive Cancer Center
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer	NCT00782379	Leukemia Lymphoma Myelodysplastic...	busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo...	18 Years - 60 Years	Northside Hospital, Inc.
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	NCT01231412	Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Chronic Lymphoc... Diffuse Large B... Hematopoietic a... Indolent Non-Ho... Mantle Cell Lym... Myelodysplastic... Myeloproliferat... Prolymphocytic ... Recurrent Chron... Recurrent Plasm... Refractory Chro... Refractory Chro... Refractory Hodg... Small Lymphocyt... T-Cell Chronic ... Waldenstrom Mac...	Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra...	-	Fred Hutchinson Cancer Center
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies	NCT02991898	Acute Lymphobla... Burkitt Lymphom... Natural Killer ... Chronic Myeloge... Myelodysplastic... Large-cell Lymp... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Hodgkin Lymphom... Multiple Myelom... Acute Myelogeno... Biphenotypic Le... Undifferentiate...	Infusion of Tre...	18 Years - 75 Years	Masonic Cancer Center, University of Minnesota
Observatory of Prolymphocytic Leukemia T	NCT04411043	Prolymphocytic ... T-cell Leukemia	Molecular carac...	18 Years -	French Innovative Leukemia Organisation
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL	NCT02296918	Chronic Lymphoc... Small Lymphocyt... Prolymphocytic ...	acalabrutinib Obinutuzumab Venetoclax Rituximab	-	Acerta Pharma BV
UCN-01 in Treating Patients With Advanced Cancer	NCT00003289	Leukemia Lymphoma Unspecified Adu...	7-hydroxystauro...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia	NCT00281931	Prolymphocytic ...	rituximab cyclophosphamid... fludarabine pho...	18 Years - 75 Years	German CLL Study Group
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias	NCT00472849	Richter's Trans... Leukemia	Oxaliplatin Fludarabine Cytarabine Rituximab Pegfilgrastim	18 Years -	M.D. Anderson Cancer Center
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	NCT00026351	Leukemia Lymphoma	rituximab pentostatin	18 Years -	National Cancer Institute (NCI)
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer	NCT00898079	Acute Undiffere... Atypical Chroni... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Solid... Chronic Lymphoc... Hairy Cell Leuk... Juvenile Myelom... Mast Cell Leuke... Neoplasm of Unc... Prolymphocytic ... Secondary Acute... T-Cell Large Gr...	Cytology Specim...	- 30 Years	Children's Oncology Group
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	NCT00005786	Extranodal Marg... Nodal Marginal ... Prolymphocytic ... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Refractory Chro... Splenic Margina... Waldenström Mac...	arsenic trioxid... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Allogeneic Stem Cell Transplant for CLL	NCT01629511	Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom...	Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus	18 Years - 70 Years	M.D. Anderson Cancer Center
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	NCT00005803	Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph...	Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT01076556	Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage II Small ... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ...	Alvocidib Hydro... Cyclophosphamid... Diagnostic Labo... Pharmacological... Rituximab	18 Years -	National Cancer Institute (NCI)
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	NCT01126502	B-cell Chronic ... Prolymphocytic ... Recurrent Small... Refractory Chro...	alvespimycin hy... diagnostic labo... pharmacogenomic... pharmacological...	18 Years -	National Cancer Institute (NCI)
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL	NCT00452374	Leukemia	Cytarabine Fludarabine Oxaliplatin Rituximab	18 Years -	M.D. Anderson Cancer Center
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases	NCT02145039	Acute Leukemias Burkitt's Lymph... Chronic Myeloge...	Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ...	- 74 Years	Masonic Cancer Center, University of Minnesota
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia	NCT02029443	Chronic Lymphoc... Small Lymphocyt... Richter's Syndr... Prolymphocytic ...	Acalabrutinib	18 Years - 130 Years	Acerta Pharma BV
Observatory of Prolymphocytic Leukemia T	NCT04411043	Prolymphocytic ... T-cell Leukemia	Molecular carac...	18 Years -	French Innovative Leukemia Organisation
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	NCT00098488	B-cell Chronic ... Prolymphocytic ... Refractory Chro...	tanespimycin rituximab	18 Years -	National Cancer Institute (NCI)
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant	NCT01244906	Hematologic Neo...	Allogeneic Hema...	18 Years - 75 Years	Northside Hospital, Inc.
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL	NCT02296918	Chronic Lymphoc... Small Lymphocyt... Prolymphocytic ...	acalabrutinib Obinutuzumab Venetoclax Rituximab	-	Acerta Pharma BV
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	NCT00005803	Prolymphocytic ... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Non-H... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... T-Cell Chronic ... T-Cell Prolymph...	Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cyclosporine Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Therapeutic Aut... Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation	NCT02285244	Prolymphocytic ... Recurrent Mantl... Recurrent Small... Refractory Chro... Richter Syndrom...	sotrastaurin ac... pharmacological... laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia	NCT02530515	Anemia Cancer Fatigue Chronic Lymphoc... Fever Infectious Diso... Lymphadenopathy Lymphocytosis Night Sweats Prolymphocytic ... Recurrent Chron... Richter Syndrom... Secondary Malig... Thrombocytopeni... Weight Loss	Ex Vivo-activat... Laboratory Biom...	-	M.D. Anderson Cancer Center
Treg Cells for AGVHD in Non-myeloablative UCB Transplant	NCT02118311	Hematologic Mal...	T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra...	18 Years - 69 Years	Masonic Cancer Center, University of Minnesota
Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	NCT01515176	Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro...	Dinaciclib Laboratory Biom... Ofatumumab Pharmacological...	18 Years -	National Cancer Institute (NCI)
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies	NCT02556931	Myelodysplastic... Chronic Myelomo... Small Lymphocyt... Chronic Lymphoc... Prolymphocytic ... Chronic Myeloid... Chronic Myelopr... Multiple Myelom... Plasma Cell Neo... Plasma Cell Dys... Myelofibrosis Polycythemia Ve... Essential Throm... Plasma Cell Leu...	Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate m...	-	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation	NCT02285244	Prolymphocytic ... Recurrent Mantl... Recurrent Small... Refractory Chro... Richter Syndrom...	sotrastaurin ac... pharmacological... laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases	NCT00309842	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelofibrosis MDS Refractory Anem... Chronic Lymphoc... Prolymphocytic ... Non-Hodgkin's L... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	filgrastim cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... total-body irra...	- 55 Years	Masonic Cancer Center, University of Minnesota
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)	NCT00364286	Leukemia Lymphoma	Dasatinib (BMS-...	-	M.D. Anderson Cancer Center
Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	NCT02007044	Prolymphocytic ... Recurrent Chron... Recurrent Small...	Ibrutinib Quality-of-Life... Questionnaire A... Rituximab	18 Years -	M.D. Anderson Cancer Center
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	NCT02303392	Prolymphocytic ... Recurrent Adult... Recurrent Mantl... Recurrent Small... Refractory Chro...	Selinexor Ibrutinib Pharmacological... Laboratory Biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial	NCT00890435	Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi...	questionnaire a... psychosocial as...	18 Years -	Children's Oncology Group
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases	NCT00376519	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... Secondary Myelo...	cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... Treg cell infus... umbilical cord ... total-body irra...	18 Years - 45 Years	Masonic Cancer Center, University of Minnesota
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease	NCT00719888	Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Burkitt Lymphom... Chronic Lymphoc... Chronic Myeloge... Chronic Phase C... Follicular Lymp... Lymphoblastic L... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Non-Hodgkin Lym... Plasma Cell Mye... Prolymphocytic ... Refractory Anem... Small Lymphocyt...	Cyclophosphamid... Cyclosporine Double-Unit Umb... Fludarabine Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... Thiotepa	6 Months - 45 Years	Fred Hutchinson Cancer Center
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases	NCT01962636	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Plasma Cell Leu... Myelofibrosis Myelodysplasia Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large B... Lymphoblastic L... Burkitt's Lymph... Non-Hodgkin Lym... Multiple Myelom...	Fludarabine Cyclophosphamid... Total Body Irra... Cyclosporine A Mycophenylate m... Umbilical cord ...	- 55 Years	Masonic Cancer Center, University of Minnesota
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial	NCT00890435	Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi...	questionnaire a... psychosocial as...	18 Years -	Children's Oncology Group
Sunitinib in Treating Patients With Idiopathic Myelofibrosis	NCT00387426	Accelerated Pha... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Atypical Chroni... Blastic Phase C... Chronic Myelomo... Chronic Phase C... Mast Cell Leuke... Meningeal Chron... Primary Myelofi... Progressive Hai... Prolymphocytic ... Recurrent Adult... Recurrent Adult... Refractory Chro... Refractory Hair... Relapsing Chron... Secondary Acute... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... T-cell Large Gr... Untreated Adult... Untreated Adult... Untreated Hairy...	sunitinib malat...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	NCT00278213	Prolymphocytic ...	alemtuzumab cyclophosphamid... fludarabine pho... mitoxantrone hy...	18 Years - 70 Years	German CLL Study Group
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases	NCT01962636	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Plasma Cell Leu... Myelofibrosis Myelodysplasia Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large B... Lymphoblastic L... Burkitt's Lymph... Non-Hodgkin Lym... Multiple Myelom...	Fludarabine Cyclophosphamid... Total Body Irra... Cyclosporine A Mycophenylate m... Umbilical cord ...	- 55 Years	Masonic Cancer Center, University of Minnesota
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL	NCT02005289	Contiguous Stag... Noncontiguous S... Prolymphocytic ... Recurrent Small... Refractory Chro... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ...	MOR00208 lenalidomide Correlative Stu...	18 Years - 80 Years	Ohio State University Comprehensive Cancer Center
Allo HSCT Using RIC and PTCy for Hematological Diseases	NCT05805605	Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis	Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M...	- 75 Years	Masonic Cancer Center, University of Minnesota
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	NCT02303392	Prolymphocytic ... Recurrent Adult... Recurrent Mantl... Recurrent Small... Refractory Chro...	Selinexor Ibrutinib Pharmacological... Laboratory Biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL	NCT02005289	Contiguous Stag... Noncontiguous S... Prolymphocytic ... Recurrent Small... Refractory Chro... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ...	MOR00208 lenalidomide Correlative Stu...	18 Years - 80 Years	Ohio State University Comprehensive Cancer Center
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases	NCT02145039	Acute Leukemias Burkitt's Lymph... Chronic Myeloge...	Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ...	- 74 Years	Masonic Cancer Center, University of Minnesota

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: